论文部分内容阅读
目的判断骨转移瘤患者经过放射性核素89SrCl2治疗后免疫学指标CD4+,CD8+及CD4+/CD8+的变化及该指标对治疗效果的监控作用。方法选择经临床确诊的应用89SrCl2治疗的患者及正常对照组各24例。用流式细胞仪分别测定各患者治疗前、后及正常对照组CD4+,CD8+及CD4+/CD8+值。每例患者均于治疗后第2,4和6个月行全身骨显像,记录骨转移病灶数及计算平均值。结果正常对照组CD4+,CD4+/CD8+值高于骨转移瘤患者,而CD8+值低于骨转移瘤患者(P<0.05)。89SrCl2治疗后病灶数随CD4+增加、CD8+降低、CD4+/CD8+增加而相应减少。第4个月89SrCl2作用达峰值,各指标也达到极限值。结论CD4+,CD8+,CD4+/CD8+可以灵敏反映89SrCl2治疗效果,客观反映骨转移瘤病灶的变化。
Objective To determine the changes of immunological markers CD4 +, CD8 + and CD4 + / CD8 + after treatment with 89SrCl2 in patients with bone metastases and to evaluate the therapeutic effect of this indicator. Methods The clinically diagnosed patients treated with 89SrCl2 and the normal control group of 24 patients. The levels of CD4 +, CD8 + and CD4 + / CD8 + were measured by flow cytometry in each group before and after treatment and in normal control group. Whole body bone imaging was performed on the 2nd, 4th, and 6th month after treatment in each patient. The number of bone metastases and the average value were recorded. Results The levels of CD4 + and CD4 + / CD8 + in normal control group were higher than those in bone metastasis and CD8 + in bone metastases (P <0.05). 89SrCl2 treatment with the number of lesions increased CD4 +, CD8 + decreased, CD4 + / CD8 + increased accordingly reduced. 89SrCl2 the role of the first four months reached its peak, the indicators have reached the limit. Conclusion CD4 +, CD8 + and CD4 + / CD8 + can reflect 89SrCl2 sensitively and objectively reflect the changes of bone metastases.